Central drugs controller - Latest News Update, Information, Photos & Videos on Central drugs controller at Lokmat Times

Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so.It had obtained approval from the Drug Controller General of India (DCGI) in late April. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd in Japan, a subsidiary of Fujifilm Corporation."Clinical trials have commenced and over 10 leading government and private hospitals in India are being enrolled for the study. Glenmark estimates study completion by July or August," it said in a statement on Tuesday.Glenmark has successfully developed the active pharma ingredient (API) and the formulations for the product through its in-house R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.The molecule if commercialised will be marketed under the brand name FabiFlu in India."Several health and medical experts both in and outside of Glenmark are eager to see the effect that Favipiravir has on Covid-19 cases," said Monika Tandon, Vice President and Head of Clinical Development, Global Specialty/Branded Portfolio at Glenmark Pharmaceuticals."We believe the study results will be significant as there is currently no effective treatment for the virus. The data we get from these trials will point us in a clearer direction with regard to COVID-19 treatment and management," she said.Sujesh Vasudevan, President for India Formulations, Middle East and Africa at Glenmark Pharmaceuticals, said: "Our effort is to launch a treatment for COVID-19 patients as soon as possible and control the spread of the pandemic. We will do all it takes to ensure the accessibility of the product across the country if the clinical trials are successful".Glenmark was the first pharmaceutical company in India to be given approval by the regulator to start the trial on COVID-19 patients in India. As per the approved clinical trial protocol, 150 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care.Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, speciality and OTC business with operations in over 50 countries. Its key therapy focus areas globally are respiratory, dermatology and oncology.( With inputs from ANI )

Central Drugs ControllerFOLLOW

Central drugs controller, Latest News

New Delhi, Jan 14 Delhi Chief Minister Arvind Kejriwal on Thursday said that the vaccination drive will be ... ...

New Delhi, Jan 14 Delhi Chief Minister Arvind Kejriwal on Thursday said that the vaccination drive will be ... ...

The Drug Controller General of India (DCGI), on Saturday gave approval for the commercial launch of India's first Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) test, developed by the Tata Group and CSIR-IGIB (Institute of Genomic ...

New Delhi, Sep 12 The Drug Controller General of India (DCGI) has directed the Serum Institute of India ... ...

Dr Reddy's Laboratories on Wednesday announced the launch of Remdesivir under the brand name Redyx for Indian markets. ...

New Delhi, Aug 6 Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to ... ...

Former honorary physician to the President of India and senior physician at Ganga Ram hospital Dr Mohsin Wali has welcomed the move of the Drug Controller General of India to give permission for emergency use of Remdesivir to treat COVID-19 patients ...

Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so. ...